Richard Hans Gomer from 9470 Lightsey Ln, College Station, TX 77845, age 68, Phone: 713 927-2736

Us Patents

Compositions And Methods For Suppressing Fibrocytes And For Detecting Fibrocyte Differentiation
view source
US Patent:

7763256, Jul 27, 2010
Filed:

Sep 27, 2006
Appl. No.:

11/535636
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 38/00
C07K 7/00
C07K 14/00
US Classification:

4241981, 514 2, 530350
Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

Wound Healing Dressing For Enhancing Fibrocyte Formation
view source
US Patent:

7935682, May 3, 2011
Filed:

Jun 22, 2005
Appl. No.:

11/158723
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 31/715
A61K 31/729
A61K 38/18
A61K 45/00
A61K 9/14
A61K 9/16
US Classification:

514 54, 424 852, 424484, 424488, 424491
Abstract:

The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the invention may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.

Compositions And Methods For Suppressing Fibrocytes
view source
US Patent:

8012472, Sep 6, 2011
Filed:

Sep 27, 2006
Appl. No.:

11/535649
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 39/395
US Classification:

4241301, 514826, 514885
Abstract:

The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.

Treatment Methods For Fibrosis Related Disorders
view source
US Patent:

8057802, Nov 15, 2011
Filed:

Dec 24, 2008
Appl. No.:

12/343606
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 38/00
C07K 7/00
C07K 14/00
US Classification:

4241981, 514 2, 530350
Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

Compositions And Methods For Suppressing Fibrocytes
view source
US Patent:

8187599, May 29, 2012
Filed:

Sep 2, 2011
Appl. No.:

13/224959
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 39/395
US Classification:

4241301, 514885
Abstract:

The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound.

Treatment Of Fibrosis Related Disorders
view source
US Patent:

8187608, May 29, 2012
Filed:

Sep 23, 2011
Appl. No.:

13/242783
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
Assignee:

William Marsh Rice University - Houston TX
International Classification:

A61K 38/00
US Classification:

4241981, 514 11, 514885
Abstract:

The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

Compositions And Methods For Suppressing Fibrocyte Differentiation From Monocytes And For Detecting Fibrocyte Differentiation
view source
US Patent:

20050238620, Oct 27, 2005
Filed:

Jun 22, 2005
Appl. No.:

11/158966
Inventors:

Richard Gomer - Houston TX, US
Darrell Pilling - Pearland TX, US
International Classification:

A61K039/395
A61K038/48
A61K038/20
A61K038/17
US Classification:

424085200, 424094630, 424130100, 514012000
Abstract:

The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.

Wound Healing Compositions, Systems, And Methods
view source
US Patent:

20100297074, Nov 25, 2010
Filed:

Apr 9, 2010
Appl. No.:

12/798729
Inventors:

Richard Hans Gomer - College Station TX, US
Darrell Pilling - Pearland TX, US
International Classification:

A61K 38/20
A61K 31/729
A61K 38/18
A61P 17/02
US Classification:

424 852, 514 54, 514 91, 514 89
Abstract:

The present disclosure relates, according to some embodiments, to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-4 and IL-3 to enhance the differentiation of monocytes into fibrocytes. Methods and compositions for binding SAP, decreasing SAP levels and suppressing SAP activity are provided. Methods of using, inter alia, CPHPC, the 4,6-pyruvate acetyl of beta-D-galactopyranose, ethanolamines, high EEO agarose, IL-4, and IL-13, and anti-SAP antibodies and fragments thereof to increase monocyte differentiation into fibrocytes are provided. These methods are useful in a variety of applications, including wound healing. Wound dressings are also provided. Finally, the disclosure may include assays for detecting the ability of various agents to modulate monocyte differentiation into fibrocytes and to detect monocyte defects.